EUCTR2009-016954-42-AT进行中(未招募)不适用
Randomized Clinical Safety and Efficacy Investigation of the Swiss Cardio Technologies Cardioplexol? Solution in comparison with Buckberg Solution - Cardioplexol Study
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.The patient is between the age of 18 and 80;
- •2.The patient’s preoperative evaluation indicates the need for a primary elective cardiac coronary artery bypass graft (CABG) operation and/or a cardiac valve repair/replacement;
- •3.The operation is carried out via a full sternotomy, under cardiac arrest and under the assistance of a heart lung machine;
- •4.The patient has signed the Patient Informed Consent Form.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 120
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 120
排除标准
- •1.pre-operative EF of less than 30%;
- •2.pre-operative IABP;
- •3.under pre-operative catecholamine support;
- •4.history of myocardial infarction within less than 7 days;
- •5.previous history of cardiac surgery, including the implantation of a pace maker or an ICD;
- •6.active myocarditis and/or endocarditis;
- •7.history of atrial fibrillation;
- •8.aortic valve insufficiency severity grade > 1 ;
- •9.history of neurologic event;
- •10.carotid artery disease;
- •11.renal insufficiency or is under dialysis;
- •12.pre-operative serum creatinine value of more than 2.0 mg/dl;
- •13.known for an hematologic disorder;
- •14.under anti-vitamin K;
- •15.history of HIT;
- •16.participating in a concomitant research study of an investigational product;
- •17.pregnant or lactating;
- •18.intravenous drug user, alcohol abuser, prisoner, institutionalized, or is unable to give informed consent;
研究者
相似试验
未知
Unknown
Investigation of the clinical safety and efficacy of iguratimod in patients with rheumatoid arthritisRheumatoid ArthritisJPRN-jRCT1080222730Toyama Chemical Co., Ltd. (Current FUJIFILM Toyama Chemical Co., Ltd.)2,000
未知
Unknown
Investigation of the clinical safety and efficacy of iguratimod in patients with rheumatoid arthritisRheumatoid ArthritisJPRN-jRCT1080222005Eisai Co., Ltd.2,000
尚未招募
Unknown
Investigation of the clinical safety and efficacy of favipiravir (Avigan tablets) in patients with novel or re-emerging influenza virus infectionsJPRN-jRCT1080223849FUJIFILM Toyama Chemical Co., Ltd. (Former Toyama Chemical Co., Ltd.)
进行中(未招募)
1 期
Randomised Clinical Study of Safety of Efficacy of Extracelular Matrix (SIS- Biodesign layer) in combination with growth factors released fromAutologous Platelet Rich Plasma Concentrate separated in the same time procedure with SmartPReP2 separator for Wound Healing.Ischemic and venous leg Ulcers will be treated with Biodesign+autologous PRP concentrate in randomised study.Chronical ischemic and venous ulcersEUCTR2013-003104-39-CZFakultní nemocnice Ostrava,Czech republic90
进行中(未招募)
不适用
A Randomized Study to Evaluate Safety and Efficacy of Transitioning Therapy From Alendronate to Denosumab (AMG 162) in Postmenopausal Women with Low Bone Mineral DensityPostmenopausal Osteoporosis/osteopeniaEUCTR2006-000849-19-EEAmgen Inc500
